Company intelligence / Profile preview

Uute Scientific

Ownership: Private
Development stage: Commercial

Overview

Recent in vivo study (October 2024) with 142 participants showed that lotion containing rich microbial biodiversity strengthens the skin's protective barrier and prevents redness and irritation[2]

Therapeutic areas: DermatologyImmunology
Modalities: Microbial extracts
Industry: Non-Drug Biotech

Drug pipeline

1 asset

Re-Connecting Nature

Commercial

Indications: Atopic dermatitis, Immune-mediated diseases

Beyond the preview

Go deeper on Uute Scientific.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Uute Scientific.

Explore the full profile